WASHINGTON — A phase 3 clinical trial revealed that the investigational vaccine candidate — known as LB6V — showed more than 70% efficacy against confirmed Lyme disease, according to results presented at IDWeek.
Kristen Dowd is a Copy Editor at various publications, including South Jersey Biz and Orlando Family Magazine. She specializes in medicine and healthcare, focusing on topics such as oncology, hematology, and public health, while also exploring themes of wellness and alternative medicine. Kristen's work has been featured in Environmental Post Ledger, FARE, and Healio.